Сингапур - Енглески - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 129.082mg eqv bosentan - tablet, film coated - 125 mg - bosentan monohydrate 129.082mg eqv bosentan 125 mg

Сингапур - Енглески - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bosentan monohydrate 64.541mg eqv bosentan - tablet, film coated - 62.5 mg - bosentan monohydrate 64.541mg eqv bosentan 62.5 mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bosentan monohydrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bosentan monohydrate -

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - bosentan monohydrate -

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg;  ; bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg - film coated tablet - 62.5 mg - active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Велика Британија - Енглески - myHealthbox

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 62.5mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Велика Британија - Енглески - myHealthbox

dr. reddy’s laboratories (uk) ltd. - bosentan - film-coated tablet - 125mg - other antihypertensives - treatment of pulmonary arterial hypertension (pah) to improve exercise capacity and symptoms in patients with who functional class iii. efficacy has been shown in: • primary (idiopathic and heritable) pulmonary arterial hypertension • pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease • pulmonary arterial hypertension associated with congenital systemic-topulmonary shunts and eisenmenger’s physiology

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bosentan monohydrate -